CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C

References

• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–67.
   PubMed Web of Science ®Google Scholar
• Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547–9.
   PubMed Web of Science ®Google Scholar
• Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899–905.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504–8.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–72.
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97–103.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993–9.
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100–4.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–45.
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Ruster B, Elez R, Weber S, Piiper A, Lee JH, Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology 2001;33:1518–26.
   PubMed Web of Science ®Google Scholar
• Hofmann WP, Herrmann E, Kronenberger B, Merkwirth C, Welsch C, Lengauer T, Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. Blood 2004;104:1228–9.
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Kessel A, Slobodin G, Sabo E, Yeshurun D, Toubi E. Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J Virol 2003;77:10432–6.
   PubMed Web of Science ®Google Scholar
• Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624–30.
   PubMed Web of Science ®Google Scholar
• Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C, In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998;91:3841–9.
   PubMed Web of Science ®Google Scholar
• Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, Richard Y, Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004;39:817–25.
   PubMed Web of Science ®Google Scholar
• Roque-Afonso AM, Ducoulombier D, Di Liberto G, Kara R, Gigou M, Dussaix E, Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005;79:6349–57.
   PubMed Web of Science ®Google Scholar
• Martin F, Roth DM, Jans DA, Pouton CW, Partridge LJ, Monk PN, Tetraspanins in viral infections: a fundamental role in viral biology? J Virol 2005;79:10839–51.
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Binding of hepatitis C virus to CD81. Science 1998;282:938–41.
   PubMed Web of Science ®Google Scholar
• Higginbottom A, Quinn ER, Kuo CC, Flint M, Wilson LH, Bianchi E, Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol 2000;74:3642–49.
   PubMed Web of Science ®Google Scholar
• Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89–109.
   PubMed Web of Science ®Google Scholar
• Chang LL, Cheng PN, Chen JS, Young KC. CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection. Antiviral Res 2007;75:43–51.
   PubMed Web of Science ®Google Scholar
• Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391–9.
   PubMed Web of Science ®Google Scholar
• Welker MW, von Wagner M, Ochs D, Zimmer V, Hofmann WP, Piiper A, Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. Dig Liver Dis 2010;42:735–40.
   PubMedGoogle Scholar
• D'Agosto G, Trento E, Nosotti L, Bordignon V, Battista M, Prignano G, CD81 expression on CD19+ peripheral blood lymphocytes is associated with chronic HCV disease and increased risk for HCV infection: a putative role for inflammatory cytokines. J Biol Regul Homeost Agents 2009;23:155–64.
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Herrmann E, Hofmann WP, Wedemeyer H, Sester M, Mihm U, Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. J Leukoc Biol 2006;80:298–308.
   PubMed Web of Science ®Google Scholar
• Soldevila B, Alonso N, Martinez-Arconada MJ, Morillas RM, Planas R, Sanmarti AM, A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4CD25CD127FoxP3 T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment. J Viral Hepat 2011;18:384–92.
   Google Scholar
• Kronenberger B, Sarrazin C, Hofmann WP, von Wagner M, Herrmann E, Welsch C, Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. J Viral Hepat 2004;11:310–18.
   PubMed Web of Science ®Google Scholar
• Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004;40:1442–9.
   PubMed Web of Science ®Google Scholar
• Ziegler S, Kronenberger B, Albrecht BA, Kaul A, Gamer AL, Klein CD, Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors. J Biomol Screen 2009;14:620–6.
   PubMedGoogle Scholar
• Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000;18:393–422.
   PubMed Web of Science ®Google Scholar
• Maecker HT, Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997;185:1505–10.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Muller U, Campbell KS. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 1997;16:4217–25.
   PubMed Web of Science ®Google Scholar
• Tsitsikov EN, Gutierrez-Ramos JC, Geha RS. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci USA 1997;94:10844–9.
   PubMed Web of Science ®Google Scholar
• Bradbury LE, Goldmacher VS, Tedder TF. The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. J Immunol 1993;151:2915–27.
   PubMed Web of Science ®Google Scholar
• Shoham T, Rajapaksa R, Kuo CC, Haimovich J, Levy S. Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol Cell Biol 2006;26:1373–85.
   PubMed Web of Science ®Google Scholar
• Duan H, Struble E, Zhong L, Mihalik K, Major M, Zhang P, Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine 2010;28:4138–44.
   PubMed Web of Science ®Google Scholar
• Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010;84:5751–63.
   PubMed Web of Science ®Google Scholar
• Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 2000;81:2873–83.
   PubMed Web of Science ®Google Scholar
• Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD Jr., Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 2009;83:12473–82.
   PubMed Web of Science ®Google Scholar
• Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 2008;82:6061–6.
   PubMed Web of Science ®Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–20.
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372–4.
   PubMed Web of Science ®Google Scholar